Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
C3a and suPAR drive versican V1 expression in tubular cells of focal segmental glomerulosclerosis
Runhong Han, … , Zhihong Liu, Hao Bao
Runhong Han, … , Zhihong Liu, Hao Bao
Published April 4, 2019
Citation Information: JCI Insight. 2019;4(7):e122912. https://doi.org/10.1172/jci.insight.122912.
View: Text | PDF | Corrigendum
Research Article Nephrology

C3a and suPAR drive versican V1 expression in tubular cells of focal segmental glomerulosclerosis

  • Text
  • PDF
Abstract

Chronic tubulointerstitial injury impacts the prognosis of focal segmental glomerulosclerosis (FSGS). We found that the level of versican V1 was increased in tubular cells of FSGS patients. Tubular cell–derived versican V1 induced proliferation and collagen synthesis by activating the CD44/Smad3 pathway in fibroblasts. Both urine C3a and suPAR were increased and bound to the tubular cells in FSGS patients. C3a promoted the transcription of versican by activating the AKT/β-catenin pathway. C3aR knockout decreased the expression of versican in Adriamycin-treated (ADR-treated) mice. On the other hand, suPAR bound to integrin β6 and activated Rac1, which bound to SRp40 at the 5′ end of exon 7 in versican pre-mRNA. This binding inhibited the 3′-end splicing of intron 6 and the base-pair interactions between intron 6 and intron 8, leading to the formation of versican V1. Cotreatment with ADR and suPAR specifically increased the level of versican V1 in tubulointerstitial tissues and caused more obvious interstitial fibrosis in mice than treatment with only ADR. Altogether, our results show that C3a and suPAR drive versican V1 expression in tubular cells by promoting transcription and splicing, respectively, and the increases in tubular cell–derived versican V1 induce interstitial fibrosis by activating fibroblasts in FSGS.

Authors

Runhong Han, Shuai Hu, Weisong Qin, Jinsong Shi, Qin Hou, Xia Wang, Xiaodong Xu, Minchao Zhang, Caihong Zeng, Zhihong Liu, Hao Bao

×

Figure 5

C3a induces versican expression by activating the AKT/β-catenin pathway in tubular cells.

Options: View larger image (or click on image) Download as PowerPoint
C3a induces versican expression by activating the AKT/β-catenin pathway ...
(A) RT-PCR analysis of total versican in tubular cells treated with C3a and SB203580, PD098059, or MK2206 (n = 5). (B) RT-PCR analysis of versican V1, V0, and V3 in tubular cells treated with C3a and MK2206 (n = 3). (C) Western blot analysis of phospho-AKT (p-AKT) in tubular cells (n = 3). (D) Western blot analysis of nuclear β-catenin in tubular cells (n = 3). (E) Schematic of the β-catenin/TCF binding sites in the upstream sequence of the versican promoter and the constructed versican promoter–luciferase reporter plasmids. (F) ChIP analysis of the binding between β-catenin and the versican promoter in tubular cells treated with C3a (n = 3). (G) Normalized luciferase activity of reporter constructs in tubular cells cotransfected with N90-β-catenin plasmid (n = 3). (H) RT-PCR analysis of total versican, versican V1, V0, and V3 in tubular cells transfected with N90-β-catenin plasmid (n = 3). (I) RT-PCR analysis of total versican, versican V1, V0, and V3 in tubular cells treated with C3a and si-CTNNB1 (n = 3). For statistical analysis, 1-way ANOVA with Tukey’s post hoc test was used for A, B, and I, and a 2-tailed Student’s t test was used for G and H. *P < 0.05 compared with control; #P < 0.05 compared with C3a-treated cells.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts